Top

Published in:

01-01-2005 | Review Article

Positron Emission Tomography Imaging of Small Animals in Anticancer Drug Development

Author: Eric O. Aboagye, PhD, MPSGH

Published in: Molecular Imaging and Biology | Issue 1/2005

Abstract

Positron emission tomography (PET) imaging of small animals enables researchers to bridge the gap between in vitro science and in vivo human studies. The imaging paradigm can be established and refined in animals before implementation in humans and image data related to ex vivo assays of biological activity. Small animal PET (saPET) imaging enables assessment of baseline focal pathophysiology, pharmacokinetics, biological target modulation and the efficacy of novel drugs. The potential and challenge of this technology as applied to anticancer drug development is discussed here.

Myers, R 2001The biological application of small animal PET imagingNucl Med Biol28585593CrossRefPubMed

Hume, SP, Myers, R 2002Dedicated small animal scanners: A new tool for drug developmentCurr Pharm Des814971511

Hume, SP, Gunn, RN, Jones, T 1998Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animalsEur J Nucl Med25173176CrossRefPubMed

Qi, JY, Leary, RM, Cherry, SR, Chatziioannou, A, Farquhar, TH 1998High-resolution 3D Bayesian image reconstruction using the micro-PET small-animal scannerPhys Med Biol4310011013CrossRef

Walledge, RJ, Reader, AJ, Aboagye, EO, et al. 20024D PET with the quad-HIDAC: Development of dynamic list-mode EM image reconstructionIEEE Nucl Sci Symp Conf Rec317161720(Conference Proceeding)CrossRef

Collingridge, DR, Glaser, M, Osman, S, et al. 2003In vitro selectivity, in vivo biodistribution and tumor uptake of annexin V radiolabelled with a positron emitting radioisotopeBr J Cancer8913271333CrossRef

Barthel, H, Cleij, MC, Collingridge, DR, et al. 20033′-deoxy-3′-[¹⁸F]Fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomographyCancer Res6337913798PubMed

Aboagye, EO, Saleem, A, Price, PM 2002Tumor imaging applications in the testing of new drugsBaguley, BCKerr, DJ eds. Anticancer drug developmentAcademic PressSan Diego353369

Gupta, N, Price, P, Aboagye, EO 2002PET for in vivo pharmacokinetic and pharmacodynamic measurementsEur J Cancer3820942107CrossRef

10.

Hammond, LA, Denis, L, Salman, U, et al. 2003Positron emission tomography (PET): Expanding the horizons of oncology drug developmentInvest New Drugs21309340CrossRef

11.

Aboagye, EO, Price, PM 2003Use of positron emission tomography in anticancer drug developmentInvest New Drugs21169181CrossRef

12.

Aboagye, EO, Saleem, A, Cunningham, V, Osman, S, Price, P 2001Extraction of 5-fluorouracil by tumor and liver: A non-invasive positron emission tomography study of patients with gastrointestinal cancerCancer Res6149374941PubMed

13.

Bading, JR, Yoo, PB, Fissekis, JD, et al. 2003Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: A positron emission tomography study in ratsCancer Res6336673674

14.

Osman, S, Luthra, SK, Brady, F, et al. 1997Studies on the metabolism of the novel antitumor agent [N-methyl-¹¹C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trialsCancer Res5721722180

15.

Saleem, A, Yap, J, Osman, S, et al. 2000Modulation of fluorouracil tissue pharmacokinetics by eniluracil: In-vivo imaging of drug actionLancet35521252131CrossRefPubMed

16.

Saleem, A, Harte, RJ, Matthews, JC, et al. 2001Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA; XR5000) in patients by positron emission tomographyJ Clin Oncol1914211429

17.

DeJesus, OT, Murali, D, Flores, LG, et al. 2003Synthesis of [F-18]-ZD1839 as a PET imaging agent for epidermal growth factor receptorsJ Label Compd Radiopharm46S1(Abstract)CrossRef

18.

Osman, S, Rowlinson-Busza, G, Luthra, SK, et al. 2001Comparative biodistribution and metabolism of carbon-11-radiolabeled N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and DNA-interacting analogsCancer Res6129352944

19.

Spaepen, K, Stroobants, S, Dupont, P, et al. 2003[(18)F]FDG PET monitoring of tumor response to chemotherapy: Does [(18)F]FDG uptake correlate with the viable tumor cell fraction?Eur J Nucl Med Mol Imaging30682688

20.

Anderson, HL, Yap, JT, Miller, MP, et al. 2003Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphateJ Clin Oncol2128232830CrossRef

21.

Bentzen, L, Keiding, S, Horsman, MR, et al. 2000Feasibility of detecting hypoxia in experimental mouse tumors with ¹⁸F-fluorinated tracers and positron emission tomography—a study evaluating [¹⁸F]fluoro-2-deoxy-D-glucoseActa Oncol39629637CrossRefPubMed

22.

Rasey, JS, Hofstrand, PD, Chin, LK, Tewson, TJ 1999Characterization of [¹⁸F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxiaJ Nucl Med4010721079PubMed

23.

Glaser, M, Collingridge, DR, Aboagye, EO, et al. 2003Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomographyAppl Radiat Isotopes585562CrossRef

24.

Collingridge, DR, Carroll, VA, Glaser, M, et al. 2002The development of [¹²⁴I]iodinated-VG76e: A novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomographyCancer Res6259125919PubMed

25.

Haubner, R, Wester, HJ, Weber, WA, et al. 2001Noninvasive imaging of alpha(v)beta3 integrin expression using ¹⁸F-labeled RGD-containing glycopeptide and positron emission tomographyCancer Res6117811785PubMed

26.

Groot-Wassink, T, Aboagye, EO, Glaser, M, Lemoine, NR, Vassaux, G 2002Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter geneHum Gene Ther1317231735CrossRefPubMed

27.

Gambhir, SS, Barrio, JR, Herschman, HR, Phelps, ME 1999Assays for noninvasive imaging of reporter gene expressionNucl Med Biol26481490CrossRef

28.

Liu, D, Hutchinson, OC, Osman, S, et al. 2002Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycinBr J Cancer87783789CrossRef

29.

Aloj, L, Caracó, C, Jagoda, E, Eckelman, WC, Neumann, RD 1999Glut-1 and hexokinase expression: Relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in cultureCancer Res5947094714

30.

Boren, J, Cascante, M, Marin, S, et al. 2001Gleevec (3STI571) influences metabolic enzyme activities and glucose carbon flow towards nucleic acid and fatty acid synthesis in myeloid tumor cellsJ Biol Chem2763774737753

31.

Sherley, JL, Kelly, TJ 1988Regulation of human thymidine kinase during the cell cycleJ Biol Chem26383508358PubMed

32.

Rasey, JS, Grierson, JR, Wiens, LW, Kolb, PD, Schwartz, JL 2002Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cellsJ Nucl Med4312101217PubMed

33.

Toyohara, J, Waki, A, Takamatsu, S, et al. 2002Basis of FLT as a cell proliferation marker: Comparative uptake studies with [³H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell linesNucl Med Biol29281287CrossRefPubMed

34.

Fischman, AJ, Bonab, AA, Livni, E, et al. 2003Evaluation of a novel CDK2 inhibitor by microPET: A comparative study of FDG and FLTMol Imaging Biol5157(Abstract)

35.

Lowe, VJ, Sarkaria, JN, Kemp, BJ, Geyer, SM, James, CD 2003Evaluation of EGFR therapy by FLT PET/CT imagingMol Imaging Biol5160(Abstract)

36.

Martin, SJ, Reutelingsperger, CP, McGahon, AJ, et al. 1995Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and AblJ Exp Med18215451556CrossRefPubMed

37.

Blakenberg, FG, Tait, J, Ohtsuki, K, Strauss, HW 2000Apoptosis: The importance of nuclear medicineNucl Med Commun21241250CrossRef

Title: Positron Emission Tomography Imaging of Small Animals in Anticancer Drug Development
Author: Eric O. Aboagye, PhD, MPSGH
Publication date: 01-01-2005
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 1/2005
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-005-0886-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Positron Emission Tomography Imaging of Small Animals in Anticancer Drug Development

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2005

Noninvasive Imaging of Cardiac Gene Expression and Its Future Implications for Molecular Therapy

Weaving Single Photon Imaging into New Drug Development

SNIDD Special Issue

Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain

Molecular Imaging in Drug Discovery and Development: Potential and Limitations of Nonnuclear Methods

A Computational Positron Emission Tomography Simulation Model for Imaging β-Amyloid in Mice